Mental and Cognitive Health Library
Every article, presentation, spotlight, and news item we've tagged to Mental and Cognitive Health.
Showing 169–192 of 215
Single MRI Predicts Alzheimer's Cognitive Decline Trajectory
Researchers developed a machine learning framework that predicts Alzheimer's disease diagnosis, cognitive decline, and future trajectory from a single baseline MRI scan combined with demographic data. This approach enables earlier identification of cognitive decline patterns before symptoms fully manifest, shifting the timeline for potential intervention.
Alzheimer’s risk gene reveals hidden bone decline in women
APOE4, a major Alzheimer's disease risk gene, compromises bone quality in women through disruption of osteocytes—the long-lived cells responsible for maintaining bone microarchitecture—despite normal appearance on standard imaging. This finding suggests bone deterioration may serve as an early, detectable signal of neurodegenerative risk before cognitive symptoms emerge.
p75 receptor preserves muscle strength aging
p75 neurotrophin receptor activation preserves the structural integrity of neuromuscular junctions and maintains muscle strength throughout aging. This mechanism represents a pathway through which neural-muscle communication can be sustained, directly opposing the decline in force production that typically accompanies advancing age.
Regulation of Lipid Dysmetabolism and Neuroinflammation Progression Linked With Alzheimer's Disease Through Modulation of Dgat2
Dgat2, an enzyme controlling triglyceride synthesis, emerges as a critical regulator linking amyloid pathology to lipid accumulation and neuroinflammation in Alzheimer's disease. Suppressing Dgat2 in animal models restores cognitive function, synaptic integrity, sleep quality, and circadian rhythms while reducing neuroinflammatory signaling, indicating a conserved therapeutic target across species.
ADDF launches new phase of $150m Alzheimer’s diagnostics accelerator
The Alzheimer's Drug Discovery Foundation has committed an additional $50 million to its Diagnostics Accelerator program, now totaling $150 million, to advance blood-based biomarkers, multi-marker panels, and AI-driven diagnostic tools for Alzheimer's disease. This investment targets earlier detection and disease monitoring to enable preventive interventions and combination therapies before irreversible neurodegeneration occurs.
Menopause linked to brain structure shifts
Post-menopausal women show measurable reductions in gray matter volume within memory and emotion-regulating brain regions, correlating with increased anxiety, depression, and sleep disruption. This structural shift represents a neuroendocrine transition point with downstream implications for cognitive resilience and cardiometabolic risk in aging.
Brain-centered longevity: why trauma recovery shapes aging
Jupiter Neurosciences acquired exclusive US rights to ALA-002, a clinical-stage psychedelic therapy for treatment-resistant PTSD and severe anxiety, signaling a strategic shift in longevity medicine toward brain-centered approaches. The deal reflects growing recognition that neurological health and trauma recovery may be foundational to aging biology itself.
Testing the redox theory of aging under parasitism
Parasitic infection accelerates oxidative stress and aging markers in host organisms, providing empirical support for redox-based aging mechanisms. This finding illuminates how chronic pathogenic burden compounds systemic dysfunction and accelerates cellular deterioration through reactive oxygen species accumulation.
Sensory Stimulation Elevates Neuroprotective Lipid Proteins
Cognito's Spectris device, a non-invasive sensory stimulation wearable, increased cerebrospinal fluid levels of HDL-like lipid transport proteins in amyloid-positive mild cognitive impairment participants. This finding suggests sensory-driven neurostimulation may modulate lipid metabolism in ways that support cognitive resilience in early Alzheimer's disease.
Urbanization, environment, and inflammaging: insights from sub-Saharan Africa
Urban environments in sub-Saharan Africa show accelerated inflammaging—chronic, low-grade systemic inflammation associated with aging—driven by environmental stressors including air pollution, pathogenic load, and dietary shifts. This research identifies modifiable environmental and lifestyle factors that influence the rate of immunological aging independent of chronological age.
Rafael Holdings gains exclusive MIT Alzheimer’s patent
Rafael Holdings secured exclusive MIT patent rights for cyclodextrin-based molecules targeting ApoE4-positive Alzheimer's disease by restoring cholesterol transport between brain cells. This represents a shift from amyloid-clearance paradigms toward addressing the cellular infrastructure that prevents pathological buildup in the first place.
AI model detects Alzheimer's pathology before symptom onset
A convolutional neural network model (AlzheiNN) achieves 99.7% accuracy in classifying Alzheimer's disease from neuroimaging data, outperforming traditional diagnostic methods. Early and accurate detection of neurodegenerative disease significantly impacts the window for intervention and the trajectory of cognitive decline.
Shared Experience of Physical Vitality and Social Participation Among Caregiving Dyads: Comparing Dyads With and Without Dementia
Caregiving relationships that maintain shared physical activity and social engagement protect against isolation and functional decline in aging adults, with dementia-affected dyads showing particular vulnerability. The structure of caregiving partnerships—whether they preserve mutual participation or devolve into dependency—predicts health trajectories independent of diagnosis.
Aging effects on emotionality, cognition and brain mononuclear cells in Sprague-Dawley rats of both sexes
Aging in rats produces sex-dependent changes in emotional regulation, cognitive function, and brain immune cell populations, with females showing greater cognitive decline and males exhibiting more pronounced emotional dysregulation. These findings suggest that neuroinflammation and immune cell dynamics contribute to cognitive and emotional aging, with implications for understanding sex-specific vulnerabilities in human neurodegenerative conditions.
Home EEG Detects Cognitive Decline Before Clinic Tests
An at-home EEG headset paired with cognitive tasks detected early speech and facial-expression changes in ALS patients over eight months—shifts that standard clinic-based testing missed. The platform demonstrated high usability and data quality among people with severe motor impairment, addressing a critical gap in how cognitive and behavioral decline are tracked in neurodegenerative disease.
Affecting a Signaling Pathway Alleviates Alzheimer’s in Mice
Somatostatin overexpression in neurons reduces microglial activation and inflammatory signaling while enhancing amyloid-β clearance in an Alzheimer's mouse model. Existing drugs targeting this pathway suggest translational potential for addressing neuroinflammation in cognitive decline.
Autophagy angle sharpens Anavex’s investment case for Alzheimer’s
Research published in PNAS Nexus proposes that autophagy dysfunction—a slowdown in cellular recycling—precedes amyloid and tau pathology in Alzheimer's disease. This upstream mechanism shifts the therapeutic target from clearing late-stage debris to restoring the cell's natural cleanup capacity earlier in disease progression.
Structural signature of plasma proteins classifies the status of Alzheimer’s disease
Plasma protein structural changes—not just abundance—distinguish Alzheimer's disease progression and predict disease status independent of traditional genetic risk markers. This approach identifies conformational biomarkers that shift with disease stage, genotype, and sex, offering a measurable window into pathological mechanisms before cognitive decline becomes severe.
Nanoplastics found in the brain raise new aging questions
Nanoplastics have been detected in human brain tissue and show correlation with neurodegenerative disease severity and accelerated aging markers. The particles' ability to cross biological barriers and interact with pathological proteins suggests chronic, low-level exposure represents a longevity risk distinct from acute toxicity.
CorTec receives FDA breakthrough device designation
The FDA granted Breakthrough Device Designation to CorTec's Brain Interchange, a fully implantable wireless brain-computer interface that uses closed-loop neural recording and adaptive stimulation to restore motor function in chronic stroke patients. Early clinical data show meaningful upper-limb recovery in patients whose progression had plateaued under conventional therapy.
Blarcamesine links functional and cognitive outcomes in AD-004 trial
Blarcamesine demonstrated a measurable correlation between MRI-detected preservation of brain volume and slowing of cognitive decline in early Alzheimer's disease, with particularly strong outcomes in a genetically defined subpopulation. Long-term data suggest a potential delay in functional deterioration of approximately 18 months over 33 months of treatment.
Anavex highlights shared autophagy biology in autism and Alzheimer’s
Anavex presents evidence linking autism spectrum disorder and Alzheimer's disease through impaired autophagy and synaptic dysfunction, proposing that restoring cellular clearance pathways via their compound Blarcamesine may address both conditions. The finding connects neurodevelopmental and neurodegenerative disease through a shared cellular mechanism, with epidemiological data showing autistic adults face substantially elevated dementia risk.
Stroke in persistent chronic kidney disease condition alters innate-immunity to escalate mitochondrial dysfunction and aging
Stroke in the context of chronic kidney disease triggers immune dysregulation that accelerates mitochondrial dysfunction and aging processes. This cascade reveals how organ system failure in one area can compromise cellular energy production and immunity simultaneously, with significant implications for longevity in populations with renal compromise.
Brain health ‘collaboratory’ focuses on non-invasive Alzheimer’s therapy
Cognito Therapeutics and Ochsner Health are partnering to test Spectris, a non-invasive neuromodulation device that delivers synchronized light and sound stimulation to restore gamma oscillations disrupted in Alzheimer's disease. Early evidence shows the approach slows cognitive decline and reduces brain volume loss, with the collaboration designed to evaluate real-world clinical implementation across diverse healthcare settings.